Monopar Therapeutics Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. The unaudited filing was signed August 10, 2023. Monopar is a clinical-stage biopharmaceutical company with no approved products or product revenue.
Financial results and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $1.595 million | $2.078 million | $3.248 million | $3.756 million |
| General and administrative | $0.733 million | $0.685 million | $1.605 million | $1.464 million |
| Total operating expenses | $2.328 million | $2.763 million | $4.853 million | $5.221 million |
| Interest income | $0.128 million | $417 | $0.219 million | $881 |
| Net loss | $2.200 million | $2.763 million | $4.635 million | $5.220 million |
| Basic and diluted loss per share | $0.16 | $0.22 | $0.35 | $0.41 |
- At June 30, cash and cash equivalents were $7.215 million and investments were $2.977 million, totaling approximately $10.191 million in cash and investments. Total assets were $10.339 million.
- Current liabilities were $2.502 million; total liabilities were also $2.502 million. The balance sheet reported no debt. Stockholders’ equity was $7.837 million and accumulated deficit was $56.439 million.
- Six-month operating cash use was $4.373 million, compared with $3.778 million in 2022. Net cash decreased $0.971 million, versus a $3.840 million decrease in the prior-year period; ATM share sales and investment maturities affected the comparison.
- Margins are not meaningful because the company reported no revenue. Management reported no substantial doubt about going concern and estimated available funds would support obligations at least through September 2024.
Material changes versus the prior comparable period
- Q2 operating expenses fell $0.435 million, primarily because R&D expense decreased $0.483 million; G&A increased $0.048 million. For the first six months, operating expenses fell $0.367 million, with lower R&D partly offset by higher G&A.
- Net loss narrowed by $0.563 million in Q2 and $0.585 million for the first six months. Higher interest income from money market accounts and investments contributed to the improvement.
- Operating cash use increased by $0.595 million for the first six months, mainly due to changes in accounts payable and accrued liabilities. The company raised net proceeds of approximately $1.467 million from ATM stock sales in the first half of 2023; it reported no common-stock sales in the first half of 2022.
- Shares issued and outstanding rose from 12.947 million at December 31, 2022 to 13.898 million at June 30, 2023. From July 1 through July 28, the company sold a further 259,860 shares for net proceeds of approximately $267,000.
Programs, outlook, and risks
- Validive: The company discontinued its Phase 2b/3 VOICE trial in March 2023 after an interim analysis did not meet the prespecified efficacy threshold. The DSMB reported no safety concerns. Monopar recorded trial close-out expenses in Q2, planned to terminate the license, and did not expect significant further Validive expense or future license and royalty obligations.
- Camsirubicin: The Phase 1b dose-escalation study was dosing two patients at the 650 mg/m2 cohort. Management described early tumor-size reductions of approximately 18% and 20%, and reported no drug-related cardiotoxicity observed to date. These are preliminary, company-reported findings, not evidence of established efficacy. Management targeted topline results by mid-2024, while noting that continued dose escalation could delay that timing.
- MNPR-101: The company and NorthStar are sharing development costs equally for radiopharmaceutical candidates. Based on preclinical results, they aimed to initiate a first-in-human imaging study with MNPR-101-Zr as early as year-end 2023. A July 2023 collaboration with the Cancer Science Institute of Singapore was to assess uPAR expression in cancer samples.
- MNPR-202: This early-stage camsirubicin analog remains in preclinical development; the filing describes laboratory findings and potential differences from doxorubicin, not clinical evidence.
- Funding: Despite its runway estimate, Monopar said it expects to seek additional capital within 12 months and requires substantial additional funding for its programs. Financing may dilute shareholders or require unfavorable debt, licensing, or collaboration terms; inability to raise funds could lead to program delays, reductions, or termination. Runway depends on assumptions that may prove incorrect.
- Other risks and contingencies: The company cited possible Nasdaq bid-price noncompliance if its share price remains below $1.00 for 30 consecutive trading days, manufacturing and clinical-trial execution risks, inflation and geopolitical disruption, and uncertainty around patient recruitment and regulatory timelines. No material legal claims were reported. Potential XOMA milestones for MNPR-101 could total up to $14.925 million if achieved; none had been triggered by June 30.
- Management stated disclosure controls were effective at June 30, 2023, and reported no material change in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Whether the September 2024 runway estimate remains valid given operating cash use, program spending, and the need for additional financing.
- Progress and timing of the camsirubicin Phase 1b trial, including dose escalation, safety, and the evidentiary basis for preliminary tumor-response statements.
- Whether the MNPR-101-Zr first-in-human study began as targeted, and the scope and funding commitments of the NorthStar and Singapore collaborations.
- Nasdaq bid-price compliance and the effect of further ATM share issuance on dilution and available capital.
- Completion of the Validive license termination and any remaining close-out costs or obligations.